

E-Filed

Date of Deposit: May 4, 2011

Attorney Docket No. 38447-201N01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT :	Christof Westenfelder	CONFIRMATION No. :	6531
SERIAL NUMBER:	10/551,317	EXAMINER:	WEHBE, Anne Marie Sabrina
FILING DATE :	August 21, 2006	ART UNIT :	1633
FOR :	STEM-CELL, PRECURSOR CELL, OR TARGET CELL-BASED TREATMENT OF MULTIORGAN FAILURE AND RENAL DYSFUNCTION		

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the above identified application. Authorization for payment of the fee set forth in 37 C.F.R. § 1.17(p) accompanies the filing of this paper.

Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart application and the communication was not **received** by any individual designated in Section 1.56(c) more than 30 days prior to the filing of this paper. Specifically, the information cited in this IDS was cited by the European Patent Office in an action dated April 21, 2011, which was received by Attorneys for Applicant on April 21, 2011.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0311, under Order No. 38447-201N01US.

Respectfully submitted,

/Sheridan Snedden/

Ivor Elrifi, Reg. No. 39,529

Sean M. Coughlin, Reg. No. 48,593

Sheridan Snedden, Reg. No. 55,998

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS

GLOVSKY and POPEO, P.C.

Tel: (858) 314-1545

Fax: (617) 542-2241

Date: May 4, 2011